Study: 2 aspirins a day keeps bowel cancer away
Source: Agencies |
October 29, 2011, Saturday
|
Print Edition
Print Edition
TAKING two aspirin tablets a day for two years reduces the long-term risk of bowel cancer in people with a family history of the disease by around 60 percent, according to a British study published yesterday.
The finding could also have implications for the wider population, though more research is needed to determine an ideal dose for different groups of people.
In recent years there has been an intense debate about the merits of routinely taking aspirin, which increases the risk of stomach ulcers and internal bleeding, but also protects against heart problems.
John Burn of Newcastle University believes his study - the first randomized controlled trial into the effect of aspirin on cancer outcomes - is a key piece of evidence validating the case for aspirin.
Previous research into cancer and aspirin, a cheap drug originally developed by Bayer more than a century ago, has been based on less robust observational studies.
Burn's study looked at people with Lynch syndrome, a genetic condition predisposing them to a range of cancers. His data suggests that for every 10,000 cancers prevented, there could be 1,000 extra ulcers due to aspirin. "There's a trade-off. If we could get by on a smaller dose, then we could potentially avoid a lot of those ulcers," Burn said.
Burn and colleagues studied 861 people with Lynch syndrome, who began a two-year course of either 600 milligrams a day of aspirin or a placebo between 1999 and 2005.
An initial analysis in 2007 found no difference in cancer rates between the groups. But it turned out the effect was delayed and in 2010 there was a clear divergence, with 19 new bowel cancers among those on aspirin and 34 in the placebo arm.
What is more, among those patients who stuck to the full two-year regimen of pill-taking - some 60 percent of the total - the effects were more pronounced, and strongly statistically significant, with a 63 percent reduction in bowel cancer cases from 23 in the placebo group versus 10 in the aspirin group.
The finding could also have implications for the wider population, though more research is needed to determine an ideal dose for different groups of people.
In recent years there has been an intense debate about the merits of routinely taking aspirin, which increases the risk of stomach ulcers and internal bleeding, but also protects against heart problems.
John Burn of Newcastle University believes his study - the first randomized controlled trial into the effect of aspirin on cancer outcomes - is a key piece of evidence validating the case for aspirin.
Previous research into cancer and aspirin, a cheap drug originally developed by Bayer more than a century ago, has been based on less robust observational studies.
Burn's study looked at people with Lynch syndrome, a genetic condition predisposing them to a range of cancers. His data suggests that for every 10,000 cancers prevented, there could be 1,000 extra ulcers due to aspirin. "There's a trade-off. If we could get by on a smaller dose, then we could potentially avoid a lot of those ulcers," Burn said.
Burn and colleagues studied 861 people with Lynch syndrome, who began a two-year course of either 600 milligrams a day of aspirin or a placebo between 1999 and 2005.
An initial analysis in 2007 found no difference in cancer rates between the groups. But it turned out the effect was delayed and in 2010 there was a clear divergence, with 19 new bowel cancers among those on aspirin and 34 in the placebo arm.
What is more, among those patients who stuck to the full two-year regimen of pill-taking - some 60 percent of the total - the effects were more pronounced, and strongly statistically significant, with a 63 percent reduction in bowel cancer cases from 23 in the placebo group versus 10 in the aspirin group.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
